30018 Federal Register / Vol. 72, No. 103 / Wednesday, May 30, 2007 / Notices 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Robert C. Moschel (NCI) et 

al. 

Relevant Publication: A manuscript 

directly related to the above technology 

will be available as soon as it is 

accepted for publication. 

Patent Status: U.S. Patent Application 

No. 11/683,310 filed 07 Mar 2007 (HHS 

Reference No. E–307–2004/1–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301/435–5560; 

madua@mail.nih.gov. 

Inhibition of ABC Transporters by 

Transmembrane Domain Analogs 

Description of Technology: ABC 

transporters contain multiple 

transmembrane domains and are 

involved in the translocation of a variety 

of substrates across cell membranes. 

Upregulation of these transporters 

contributes to multiple drug resistance 

in cancer chemotherapy wherein these 

transporters export chemotherapeutic 

agents out of cancer cells. The inventors 

have found that P-glycoprotein and 

ABCG2 transporter can be effectively 

inhibited by properly modified peptides 

corresponding to certain transmembrane 

domains. This inhibition can be used to 

overcome drug resistance in resistant 

tumors. 

Applications: Therapeutics that 

enhance cancer treatments. 

Market: Cancer is the second leading 

cause of death in the United States; 

600,000 deaths caused by cancer in 

2006; Worldwide incidence of new 

cancer patients is forecast to increase 

from 4.2 million cases in the major 

cancer markets in 2005 to 4.6 million in 

2010; Global anticancer market was 

worth over $42 billion in 2005 and by 

2010, the global cancer market is 

expected to generate sales in excess of 

$60 billion. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Nadya I. Tarasova et al. 

(NCI) 

Publications: 

1. NI Tarasova et al. Transmembrane 

inhibitors of P-glycoprotein, an ABC 

transporter. J Med Chem. 2005 Jun 

2;48(11):3768–3775. 

2. NI Tarasova et al. Inhibition of Gprotein-coupled receptor function by 

disruption of transmembrane domain 

interactions. J Biol Chem. 1999 Dec 

3;274(49):34911–34915. 

Patent Status: U.S. Patent Application 

No. 10/130,192 filed 13 May 2002 (HHS 

Reference No. E–019–2000/2–US–02); 

PCT Patent Application No. PCT/ 

US2000/31817 filed 17 Nov 2000 (HHS 

Reference No. E–019–2000/2–PCT–01); 

U.S. Provisional Patent Application No. 

60/166,767 filed 22 Nov 1999 (HHS 

Reference No. E–019–2000/1–US–01); 

U.S. Provisional Patent Application No. 

60/166,382 filed 18 Nov 1999 (HHS 

Reference No. E–019–2000/0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Structural Biophysics Laboratory is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

inhibitors of multiple drug resistance 

proteins. Please contact John D. Hewes, 

Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: May 21, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–10332 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group; Subcommittee 

F—Manpower & Training; NCI–F. 

Date: June 13–14, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Lynn M. Amende, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8105, 

Bethesda, MD 20892, 301–451–4759, 

amendel@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; CA 07–505, 

‘‘The American College of Radiology Imaging 

Network (ACRIN) (Limited Competition 

U01).’’

Date: June 20–21, 2007. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Park Hyatt Philadelphia, Broad and 

Walnut Streets, Philadelphia, PA 19102. 

Contact Person: Kenneth L. Bielat, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 7147, 

Bethesda, MD 20852, 301–496–7576, 

bielatk@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: May 22, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2664 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center on Minority Health and 

Health Disparities; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council on Minority 

Health and Health Disparities. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 72, No. 103 / Wednesday, May 30, 2007 / Notices 30019 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Minority Health and Health 

Disparities. 

Date: June 26, 2007. 

Closed: 8:30 a.m. to 10 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Open: 10 a.m. to 5 p.m. 

Agenda: The agenda will include Opening 

Remarks, Administrative Matters, Director’s 

Report, NCMHD, Concept Clearance Report, 

Health Disparities Research Update, 

Scientific Program Presentations, and other 

business of the Council. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Donna Brooks, Asst. 

Director for Administration, National Center 

on Minority Health and Health Disparities, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 800, Bethesda, MD 

20892, 301–435–2135, 

brooksd@ncmhd.nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Dated: May 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2662 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Research Grant 

Review Panel. 

Date: June 29, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites Hotel at the Chevy 

Chase Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Houmam H. Araj, PhD, 

Scientific Review Administrator, Division of 

Extramural Research, National Eye Institute, 

NIH, 5635 Fishers Lane, Suite 1300, 

Bethesda, MD 20892–9602, 301–451–2020, 

haraj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: May 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2661 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Genome Research 

Review Committee, June 8, 2007, 1 p.m. 

to June 8, 2007, 3 p.m., National 

Institutes of Health, 5635 Fishers Lane, 

Bethesda, MD 20892, which was 

published in the Federal Register on 

May 17, 2007, 72 FR 95, page 27822. 

The GNOM–G telephone conference 

date is changed from June 8, 2007, to 

June 14, 2007. The meeting time 

remains 1 p.m. to 3 p.m. The meeting 

is closed to the public. 

Dated: May 23, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2663 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Conflict SEP. 

Date: June 14, 2007. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Suite 4076, Bethesda, MD 

20892, (Telephone Conference Call). 

Contact Person: Ken D. Nakamura, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, National Human Genome 

Research Institute, National Institutes of 

Health, 5635 Fishers Lane, Suite 4076, MSC 

9306, Rockville, MD 20852, 301–402–0838, 

nakamurk@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: May 22, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2666 Filed 5–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 


sroberts on PROD1PC70 with NOTICES